Learn how you can stall the development of full-blown Multiple Myeloma with evidence-based nutritional and supplementation therapies.
Click the orange button to the right to learn more.
A diagnosis of pre-myeloma, SBP, MGUS or SMM isn’t necessarily worrisome by itself. It is the possibility of a diagnosis of full-blown multiple myeloma (MM) that causes fear, anger and depression. At least my pre-myeloma diagnosis did for me back in early 1994.
What if you could undergo evidence-based, non-toxic therapies shown to reduce the risk of MM?
Even if you have been diagnosed with either MGUS or SMM you may not have the diagnostic information about your pre-multiple myeloma to be able to determine your risk of progression to MM.
And even if you are able to determine your risk of progression to MM, experience has shown me that evidence-based, non-toxic therapies can reduce your risk of progression to MM. Please understand, I did everything my oncologist told me to do and I still relapsed and reached end-stage MM. Back in the fall of 1997.
My experience is that conventional oncology just doesn’t understand pre-multiple myeloma- AKA
I’ve included the information in the studies linked and excerpted below in this post because it gives you a sense of where the understanding is about the risk of pre-mm becoming full mm in 2011.
If you do not want to “watch and wait” to see if your MGUS/SMM progresses to Multiple Myeloma please watch the short video below:
Consider MGUS Therapies such as:
“Monoclonal gammopathy of unknown significance (MGUS) and smoldering multiple myeloma (SMM) are asymptomatic plasma cell dyscrasias, with a propensity to progress to symptomatic MM.
In recent years there have been improvements in risk stratification models (involving molecular markers) of both disorders, which have led to better understanding of the biology and probability of progression of MGUS and SMM.
In the context of numerous molecular events and heterogeneous risk of progression, developing individualized risk profiles for patients with MGUS and SMM represents an ongoing challenge that has to be addressed by prospective clinical monitoring and extensive correlative science.
In this review we discuss the current standard of care of patients with MGUS and SMM, the use of risk models, including flow cytometry and free-light chain analyses, for predicting risk of progression. Emerging evidence from molecular studies on MGUS and SMM, involving cytogenetics, gene-expression profiling, and microRNA as well as molecular imaging is described. Finally, future directions for improving individualized management of MGUS and SMM patients, as well as the potential for developing early treatment strategies designed to delay and prevent development of MM are discussed…
Predicting progression with current clinical risk models-
The Mayo Clinic risk stratification model for MGUS identifies 3 major risk factors for progression:
At 20 years of follow-up, absolute risk of progression for MGUS patients with 0, 1, 2, and 3 risk factors is
For SMM, risk factors for progression include
Cumulative risk of progression at 10 years for SMM patients with 1, 2, and 3 risk factors is:
“A recent pilot study found that curcumin, in certain patients with monoclonal gammopathy of undetermined significance (MGUS), decreases the paraprotein load and the urinary N-telopeptide of type 1 collagen bone turnover marker…